等待開盤 03-26 09:30:00 美东时间
-3.370
-1.63%
今日重点评级关注:HC Wainwright & Co.:维持OCUGEN"买入"评级,目标价从7美元升至10美元;HC Wainwright & Co.:维持Maze Therapeutics"买入"评级,目标价从60美元升至110美元
今天 11:41
今日重点评级关注:Guggenheim:维持Cabaletta Bio"买入"评级,目标价从15美元升至16美元;HC Wainwright & Co.:维持Palvella Therapeutics"买入"评级,目标价从255美元升至270美元
03-25 10:31
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:32
Progressive prices USD 2 billion of senior notes offering Progressive priced a USD 1.5 billion offering of senior notes. The issuance includes USD 500 million of 4.60% senior notes due 2031 and USD 1.0 billion of 5.15% senior notes due 2036. The 2031 notes were priced at 99.987% of par and the 2036
03-24 10:08
BRIEF-Progressive Prices $1.5 Billion Of Senior Notes March 23 (Reuters) - Progressive Corp PGR.N : PROGRESSIVE PRICES $1.5 BILLION OF SENIOR NOTES PROGRESSIVE CORP - PRICING OF $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 4.60% SENIOR NOTES DUE 2031 PROGRESSIVE CORP - PRICING OF $1 BILLION AGGREG
03-24 10:08
今日重点评级关注:HC Wainwright & Co.:维持Perspective Therapeutics"买入"评级,目标价从12美元升至13美元;Litchfield Hills:维持Star Equity Holdings"买入"评级,目标价从21美元升至28美元
03-24 10:07
Progressive prices USD 2 billion senior notes offering Progressive priced an underwritten public offering of USD 1.5 billion of senior notes. The issuance includes USD 500 million of 4.6% senior notes due 2031 and USD 1.0 billion of 5.15% senior notes due 2036. The 2031 notes were priced at 99.99% o
03-24 10:06
The Progressive Corporation announced the pricing of $500 million in 4.60% Senior Notes due 2031 and $1 billion in 5.15% Senior Notes due 2036 in a public offering. The 2031 notes were priced at 99.987% of par, and the 2036 notes at 99.676% of par. Goldman Sachs & Co. LLC and TD Securities (USA) LLC are acting as joint bookrunners. The offering is pursuant to an effective registration statement on Form S-3 filed with the SEC. Summary length: 1...
03-24 02:06
Progressive Corporation Announced Annual Shareholder Meeting Progressive will hold its annual meeting online on May 8, 2026. Shareholders will vote on the election of 11 director nominees to one-year terms. An advisory vote will be held on approval of the executive compensation program. Shareholders
03-23 19:24
今日重点评级关注:瑞穗:维持RELMADA THERAPEUTICS"跑赢大市"评级,目标价从10美元升至19美元;奥本海默:维持Pelthos Therapeutics"跑赢大市"评级,目标价从60美元升至62美元
03-23 13:53